Hookipa Pharma (NASDAQ:HOOK) Given New $7.00 Price Target at JMP Securities

Hookipa Pharma (NASDAQ:HOOK) had its price target decreased by JMP Securities from $24.00 to $7.00 in a research note issued to investors on Thursday,Benzinga reports. JMP Securities currently has a market outperform rating on the stock.

Separately, Royal Bank of Canada decreased their price objective on shares of Hookipa Pharma from $50.00 to $48.00 and set an “outperform” rating on the stock in a report on Friday, November 15th.

Hookipa Pharma Stock Performance

Shares of NASDAQ HOOK traded up $0.02 during mid-day trading on Thursday, reaching $2.32. 9,153 shares of the company’s stock were exchanged, compared to its average volume of 57,692. The firm has a market capitalization of $27.98 million, a price-to-earnings ratio of -0.62 and a beta of 0.84. Hookipa Pharma has a 52-week low of $2.19 and a 52-week high of $11.30. The company’s 50-day moving average is $3.90 and its 200-day moving average is $5.56.

Hedge Funds Weigh In On Hookipa Pharma

Several institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its stake in shares of Hookipa Pharma by 38.4% in the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after purchasing an additional 83,800 shares during the period. Ikarian Capital LLC purchased a new position in Hookipa Pharma in the 3rd quarter valued at approximately $228,000. Acadian Asset Management LLC boosted its position in Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after buying an additional 108,844 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of Hookipa Pharma during the first quarter worth $31,000. 63.88% of the stock is owned by institutional investors and hedge funds.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.